MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma

A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma

(2017) Moshe C. Ornstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators

(2017) Riccardo Mezzadra et al.   NATURE

CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

(2017) Marian L. Burr et al.   NATURE

miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions

(2017) Chih-Hung Chou et al.   NUCLEIC ACIDS RESEARCH

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Immune suppressive mechanisms in the tumor microenvironment

(2016) David H Munn et al.   CURRENT OPINION IN IMMUNOLOGY

IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).

(2016) Jean H. Hoffman-Censits et al.   JOURNAL OF CLINICAL ONCOLOGY

Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers

(2016) Keisuke Kataoka et al.   NATURE

MYC regulates the antitumor immune response through CD47 and PD-L1

(2016) S. C. Casey et al.   SCIENCE

Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity

(2016) R. D. Dorand et al.   SCIENCE

SnapShot: Renal Cell Carcinoma

(2015) Samra Turajlic et al.   CELL

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

MicroRNA-513 Regulates B7-H1 Translation and Is Involved in IFN- -Induced B7-H1 Expression in Cholangiocytes

(2014) A.-Y. Gong et al.   JOURNAL OF IMMUNOLOGY

MicroRNA silencing for cancer therapy targeted to the tumour microenvironment

(2014) Christopher J. Cheng et al.   NATURE

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

miRDB: an online resource for microRNA target prediction and functional annotations

(2014) Nathan Wong et al.   NUCLEIC ACIDS RESEARCH

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2013) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

Clear cell renal cell carcinoma associated microRNA expression signatures identified by an integrated bioinformatics analysis

(2013) Jiajia Chen et al.   Journal of Translational Medicine

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

(2012) Suzanne L Topalian et al.   CURRENT OPINION IN IMMUNOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current and future systemic treatments for renal cell carcinoma

(2012) Rosalie Fisher et al.   SEMINARS IN CANCER BIOLOGY

Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis

(2010) Nobuyoshi Kosaka et al.   CANCER SCIENCE